Ładuje się......
Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years
BACKGROUND: Few data exist concerning conversion to secondary progressive MS in patients treated with disease-modifying therapies. OBJECTIVE: Determine the proportion of alemtuzumab-treated patients converting from relapsing-remitting to secondary progressive MS during the CARE-MS core and extension...
Zapisane w:
| Wydane w: | Mult Scler J Exp Transl Clin |
|---|---|
| Główni autorzy: | , , , , , , , , , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
SAGE Publications
2020
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7750777/ https://ncbi.nlm.nih.gov/pubmed/33414927 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217320972137 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|